Novartis, CH0012005267

Novartis wins EU Cosentyx approval as Novartis stock trades at EUR 137.81

Published on 10/22/2026 at 10:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The EU approved Cosentyx for PMR on October 21, 2026. Novartis stock costs EUR 137.81 on October 22, 2026 beside a USD 292.6 billion value.

Cosentyx approval and upcoming dates

The European Commission approved Cosentyx for polymyalgia rheumatica on October 21, 2026.
The Phase III REPLENISH trial doubled sustained remission rates at Week 52.
Novartis stock trades at EUR 137.81 at 10:02 a.m. CEST at Lang & Schwarz on October 22, 2026.
Novartis will hold a remibrutinib investor call on October 23, 2026.

Pharmatechniker an Tablettenpresse, dokumentarische SW-Fotografie mit Industrieatmosphäre — Novartis AG CH0012005267 – Pharmatechniker bedient eine industrielle Tablettenpresse in dokumentarischer Schwarzweißfotografie, Illustration mit AI erstellt.

Novartis (ISIN CH0012005267) trades at EUR 137.81 at Lang & Schwarz on October 22, 2026 at 10:02 a.m. CEST. The European Commission approved Cosentyx for polymyalgia rheumatica on October 21, 2026, extending the drug's European use in immunology.

According to Novartis, Cosentyx is the first interleukin-17A inhibitor approved in Europe for adults with polymyalgia rheumatica. The approval covers patients who respond inadequately to glucocorticoids or relapse while reducing their steroid dose.

What does Cosentyx approval add?

The regulatory decision was supported by the Phase III REPLENISH trial. The trial showed that Cosentyx doubled sustained remission rates versus placebo at Week 52, giving the approval a quantified clinical basis.

For Novartis, the new indication adds another use for an established medicine rather than introducing a new product. The company said additional regulatory reviews for the polymyalgia rheumatica indication remain underway in the United States and Japan.

Three dated portfolio steps

Novartis received a positive European committee opinion for Cosentyx on September 18, 2026; received FDA approval for Rhapsido in symptomatic dermographism on October 7, 2026; and secured the European Commission approval for Cosentyx on October 21, 2026.

Which dates come next?

Novartis has scheduled a remibrutinib in multiple sclerosis investor call for October 23, 2026, followed by third-quarter results on October 27, 2026, according to its investor calendar. The company lists the results webcast for 8:00 a.m. EDT.

Stock value and trading context

Novartis had a market capitalization of USD 292.6 billion as of October 21, 2026. Its primary-market quote showed a 52-week range of USD 121.57 to USD 170.46 on the same dated market snapshot, placing the business in a large-cap pharmaceutical context.

For investors, the approval creates a measurable commercial question: whether a broader Cosentyx label can translate the trial result into prescribing and reimbursement demand. The October 23 investor call and October 27 results are the next scheduled company milestones.

Novartis stock was trading at EUR 137.81 at Lang & Schwarz on October 22, 2026 at 10:02 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Novartis stock.